ALTH Allos Therapeutics, Inc. (MM)

Allos to Discuss ODAC Panel Recommendation on Monday May 3, 2004 WESTMINSTER, Colo., April 30 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. will hold a conference call Monday afternoon to discuss the outcome of the Oncologic Drugs Advisory Committee (ODAC) meeting on the company's investigational radiation sensitizer, RSR13 (efaproxiral). Investors and media are invited to participate. Time: 5:15 PM EDT* Date: Monday, May 3, 2004 Location: The Hilton Hotel, Gaithersburg, MD Dial-in: (800) 915-4836 / (973) 317-5319 international Webcast: http://www.allos.com/ (homepage and investor relations section) *If the ODAC meeting continues past 5:15 PM, the start of the conference call will be delayed until after the meeting's conclusion. Interested parties unable to participate in the live conference call may access a recorded rebroadcast by dialing 1-800-428-6051, or +1-973-709-2089 for international callers; the conference ID number is 353015. The replay will be available from 7:00 p.m. ET on Monday, May 3, 2004 until 11:59 PM ET on May 10, 2004. In addition, the webcast will be archived for on-demand listening for 30 days at http://www.allos.com/. About Allos Therapeutics, Inc. Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. The company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy. In addition, Allos is developing PDX, an injectable small molecule chemotherapeutic agent that has a superior potency and toxicity profile relative to methotrexate and other dihydrofolate reductase, or DHFR, inhibitors. For more information, please visit the company's web site at: http://www.allos.com/. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Monique M. Greer VP, Corporate Communications and Investor Relations of Allos Therapeutics, Inc., +1-970-215-3260, ; or Media, Fern Lazar, +1-917-362-2264, or Amy Raskopf, +1-917-673-5775, both of Lazar Partners Limited, +1-212-867-1762, for Allos Therapeutics, Inc. Web site: http://www.allos.com/

Copyright